1. Home
  2. COCP vs LEXX Comparison

COCP vs LEXX Comparison

Compare COCP & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cocrystal Pharma Inc.

COCP

Cocrystal Pharma Inc.

N/A

Current Price

$1.02

Market Cap

15.3M

Sector

Health Care

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

N/A

Current Price

$0.68

Market Cap

16.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
COCP
LEXX
Founded
2006
2004
Country
United States
Canada
Employees
N/A
7
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.3M
16.2M
IPO Year
2011
N/A

Fundamental Metrics

Financial Performance
Metric
COCP
LEXX
Price
$1.02
$0.68
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$6.00
$1.50
AVG Volume (30 Days)
34.1K
131.8K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
8.02
N/A
EPS
N/A
N/A
Revenue
$12,712,091.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$601.47
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.86
$0.46
52 Week High
$2.19
$1.90

Technical Indicators

Market Signals
Indicator
COCP
LEXX
Relative Strength Index (RSI) 53.39 48.50
Support Level $1.00 $0.58
Resistance Level $1.11 $0.83
Average True Range (ATR) 0.06 0.08
MACD 0.00 0.01
Stochastic Oscillator 53.30 40.90

Price Performance

Historical Comparison
COCP
LEXX

About COCP Cocrystal Pharma Inc.

Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: